

Professeur Pierre PETIT

SERVICE :
Pharmacologie
Médicale et
Toxicologie

ÉQUIPE MÉDICALE :
Pharmacologie
clinique et
vigilances associées

FONCTION :
PUPH

CONTACT



Pr Pierre PETIT

@ ME CONTACTER

PRENEZ RENDEZ-VOUS

Secrétariat de consultations
📞 04 67 33 97 02

👤 Connexion à l'espace professionnel

Courriel
@Contacter

CONSULTATIONS



Psychiatrie polyvalente

Thérapies cognitives et comportementales

PUBLICATIONS



Ouvrages :

Petit P., Boulenger JP. : Indications frontières et dérives de prescription (Chapitre 18). *In*: Les Antidépresseurs. E. Corruble (ed.), *Médecine Sciences Publications*, Lavoisier, Paris, 2013, pp 205–215.

Petit P. Précis de Psychopharmacologie Médicale. *Sauramps Médical Édition*, Montpellier, 2011 (205 pages).

Principales publications des dix dernières années (2014–2004):

Bardy G., Cathala P., Eiden C., Baccino E., **Petit P.**, Mathieu O. An unusual case of death probably triggered by the association of buprenorphine at therapeutic dose with ethanol and benzodiazepines and with very low norbuprenorphine level. *J Forensic Sci*, 2014, *sous presse*.

Faillie JL., Babai S., Crépin S., Bres V., Laroche ML., Le Louet H., **Petit P.**, Montastruc JL., Hillaire-Buys D. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. *Acta Diabetologica*, 2014, 51, 491-497.

Faillie JL., **Petit P.**, Montastruc JL., Hillaire-Buys D. Scientific evidence and controversies about pioglitazone and bladder cancer: which lessons can be drawn? *Drug Safety*, 2013, 36, 693-707.

Eiden C., Mathieu O., Cathala P., Debruyne D., Baccino E., **Petit P.**, Peyrière H. Toxicity and death following recreational use of 2-pyrrolidino valerophenone. *Clinical Toxicology*, 2013, 51, 899-903.

Eiden C., Léglise Y., Bertomeu L., Clavel V., Faillie JL., **Petit P.**, Peyrière H. New formulation of methadone for opioid dependence in France : Acceptability and diversion/misuse liability. *Thérapie*, 2013, 68, 107-111.

Vaquer G., Magous R., Cros G., Wojtuszczyz A., Renard E., Chevassus H., **Petit P.**, Lajoix AD., Oiry C. Short-term intravenous insulin infusion is associated with reduced expression of NADPH oxidase p47phox subunit in monocytes from type 2

diabetes patients. *Fundam. Clin. Pharmacol.*, 2013, 27, 669–671.

Chevassus H., Farret A., Gagnol JP., Ponçon CA., Costa F., Roux C., Galtier F., **Petit P.** Psychological and physiological effects of bupropion compared to methylphenidate after prolonged administration in healthy volunteers (NCT00285155). *Eur. J. Clin. Pharmacol.*, 2013, 69, 779–787.

Hillaire-Buys D., Faillie JL., Montastruc JL., **Petit P.** Stay vigilant: a glitazone (pioglitazone) can hide a glitazar! *Eur J Clin Pharmacol*, 2012, 68, 1681–1683.

Leconet W., **Petit P.**, Péraldi-Roux S., Bresson D. Non-viral delivery of small interfering RNA into pancreas-associated immune cells prevents autoimmune diabetes. *Molecular Therapy*, 2012, 20, 2315–2325.

Galtier F., Mura T., Raynaud de Mauverger E., Chevassus H., Farret A., Gagnol JP., Costa F., Dupuy A., **Petit P.**, Cristol JP., Mercier J., Lacampagne A. Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers. *Toxicol. Appl. Pharmacol.*, 2012, 263, 281–286.

Mezghenna K., Pomiès P., Chalançon A., Castex F., Niclaus N., Nadal B., Cambier L., Cazevielle C., **Petit P.**, Gomis R., Berney T., Gross R, and Lajoix A.D. Increased neuronal NO synthase dimerization is involved in pancreatic beta cell hyperactivity in obesity. *Diabetologia*, 2011, 54, 2856–2866.

Youl E., Bardy G., Magous R., Cros G., Sejalon F., Virsolvy A., Richard S., Quignard JF., Gross R., **Petit P.**, Bataille D., Oiry C. Quercetin potentiates insulin secretion and protects INS-1 pancreatic β -cells against oxidative damage via the ERK1/2 pathway. *Br. J. Pharmacol.*, 2010, 161, 799–814.

Roux C., Chevassus H., Farret A., Costa F., **Petit P.**, Galtier F. Selecting healthy volunteers in specific populations: a retrospective analysis of clinical and laboratory screening. *Fundam. Clin. Pharmacol.*, 2010, 24, 121–127.

Chevassus H., Gaillard JB., Farret A., Costa F., Gabillaud I., Mas E., Dupuy AM., Michel F., Cantié C., Renard E., Galtier F., **Petit P.** A fenugreek seed extract selectively reduces spontaneous fat intake in overweight subjects. *Eur. J. Clin. Pharmacol.*, 2010, 66, 449–455.

Petit P., Lajoix AD., Gross R. P2 purinergic signalling in the pancreatic β -cell: control of insulin secretion and pharmacology. *Eur. J. Pharm. Sci.*, 2009, 37, 67–75.

Chevassus H., Molinier N., Costa F., Galtier F., Renard E., **Petit P.** A fenugreek seed extract selectively reduces spontaneous fat consumption in healthy volunteers. *Eur J Clin Pharmacol*, 2009, 65, 1175–1178.

Faruque OM., Le-Nguyen D., Lajoix AD., Vives E., **Petit P.**, Bataille D., Hani EH. Cell-Permeable Peptide-based Disruption of Endogenous PKA-AKAP Complexes: A Tool for Studying the Molecular Roles of AKAP-mediated PKA Subcellular Anchoring. *Am. J. Physiol.-Cell Physiol.*, 2009, 296, C306–316.

Tousch D., Lajoix AD., Hosy E., Azay-Milhau J., Ferrare K., Jahannault C., Cros G., **Petit P.** Chicoric acid, a new compound able to enhance insulin release and glucose uptake. *Biochem. Biophys. Res. Commun.*, 2008, 377(1), 131–135.

Lugo-Garcia L., Nadal B., Gomis R., **Petit P.**, Gross R., Lajoix A.D.: Human pancreatic

islets express the purinergic P2Y₁₁ and P2Y₁₂ receptors. *Horm. Metab. Res.*, 2008, 40, 827–830.

Farret A., Chevassus H., Roux B., **Petit P.**, Galtier F.: Direct rosiglitazone-induced modifications in insulin secretion, action and clearance: a single dose, hyperglycaemic clamp study. *Diabetologia*, 2007, 50, 1384–1387.

Lugo-Garcia L., Filhol R., Lajoix A-D., Gross R., **Petit P.**, Vignon J.: Expression of purinergic P2Y receptor subtypes by INS-1 insulinoma β -cells: a molecular and binding characterization. *Eur. J. Pharmacol.*, 2007, 568, 54–60.

Lajoix A-D., Badiou S., Péraldi-Roux S., Chardès T., Dietz S., Aknin C., Tribillac F., **Petit P.**, Gross R.: Protein inhibitor of a neuronal nitric oxide synthase (PIN) is a new regulator of glucose induced-insulin secretion. *Diabetes*, 2006, 55, 3279–3288.

Farret A., Filhol R., Linck N., Manteghetti M., Vignon J., Gross R., **Petit P.**: P2Y receptor mediated modulation of insulin release by a novel generation of 2-substituted-5'-O-(1-boranotriphosphate)-adenosine analogues. *Pharm. Res.*, 2006, 23, 2665–2671.

Farret A., Lugo-Garcia L., Galtier F., Gross R., **Petit P.** Pharmacological interventions that directly stimulate or modulate insulin secretion from pancreatic β -cell: implications for the treatment of type 2 diabetes. *Fundam. Clin. Pharmacol.*, 2005, 19, 647–656.

Léon C., Freund M., Latchoumanin O., Farret A., **Petit P.**, Cazenave P., Gachet C.: The P2Y₁ receptor is involved in the maintenance of glucose homeostasis and in insulin secretion in mice. *Purinergic Signalling*, 2005, 1, 145–151.

Montpied P., Domingo N., Senft M., Portugal H., **Petit P.**, Chanussot F.: High-fat diets impede the lowering effect of cyclosporin A on rat brain lipids and interact with the expression of apolipoproteins E and J. *Lipids*, 2005, 40, 59–67.

Chapal N., Molina L., Molina F., Laplanche M., Pau B., **Petit P.** : Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer. *Fundam. Clin. Pharmacol.*, 2004, 18, 413–422.

Farret A., Vignaud M., Dietz S., Vignon J., **Petit P.**, Gross R. : P2Y purinergic potentiation of glucose-induced insulin secretion and pancreatic β -cell metabolism. *Diabetes*, 2004, 53 (Suppl 3), S63–S66.

Rchid H., Chevassus H., Nmila R., Guiral C., **Petit P.**, Chokairi M., Sauvaire Y. *Nigella sativa* seed extracts enhance glucose-induced insulin release from rat isolated Langerhans islets. *Fundam. Clin. Pharmacol.*, 2004, 18, 525–529.

Lajoix A.D., Pugnère M., Roquet F., Mani J.C., Dietz S., Linck N., Faurie F., Ribes G., **Petit P.**, Gross R. : Changes in the dimeric state of neuronal NO synthase affect the kinetics of secretagogue-induced insulin response. *Diabetes*, 2004, 53, 1467–1474.

Broca C., Breil V., Cruciani-Guglielmacci C., Manteghetti M., Rouault C., Derouet M., Rizkalla S., Pau B., **Petit P.**, Ribes G., Ktorza A., Gross R., Reach G., Taouis M.: The insulinotropic agent ID1101 (4-hydroxyisoleucine) activates insulin signaling in rat. *Am. J. Physiol. (Endocrinol. Metab.)*, 2004, 287, E463–E471.

Chevassus H., Mourand I., Molinier N., Lacarelle B., Brun J.F., **Petit P.**: Assessment of

single-dose benzodiazepines on insulin secretion, insulin sensitivity and glucose effectiveness in healthy volunteers: a double-blind, placebo-controlled, randomized cross-over trial [ISRCTN08745124]. *BMC Clin. Pharmacol*, 2004, 4 :3 (pp. 1-10).

TRAVAUX DE RECHERCHE



Pharmacologie expérimentale et pharmacologie clinique (*psychopharmacologie et pharmacologie endocrino-métabolique*)

CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER

191 av. du Doyen Giraud
34295 Montpellier cedex 5